Results 11 to 20 of about 159,806 (339)
European Journal of Cardio-Thoracic Surgery, 2018 The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS)
M. Valgimigli +17 more
semanticscholar +3 more sources
Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk.
New England Journal of Medicine, 2021 BACKGROUND The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear.
M. Valgimigli +29 more
semanticscholar +1 more source
Catheterization and cardiovascular interventions, 2023 At least 1 month of dual antiplatelet therapy is required after coronary stenting. The aim of this all‐comers retrospective registry study was to assess the efficacy and safety of percutaneous coronary intervention (PCI) using drug‐coated balloon (DCB ...
Alma Räsänen +4 more
semanticscholar +1 more source
British Journal of Pharmacology, 2006 British Journal of Pharmacology (2006) 147, S241–S251.
Gustav, Born, Carlo, Patrono
openaire +2 more sources
Dual Antiplatelet Therapy: A Concise Review for Clinicians
Life, 2023 Dual antiplatelet therapy (DAPT) combines two antiplatelet agents to decrease the risk of thrombotic complications associated with atherosclerotic cardiovascular diseases. Emerging data about the duration of DAPT is being published continuously.
H. H. Virk +9 more
semanticscholar +1 more source
British Journal of Haematology, 2008 SummaryPlatelets play a major role in thromboembolic diseases, and so antiplatelet therapy remains crucial in treatment and prophylaxis. Upon vascular injury, platelets rapidly adhere to the exposed subendothelial matrix, after which they become activated, resulting in the recruitment of additional platelets from the circulation to eventually form a ...
Simon F, De Meyer +4 more
openaire +2 more sources
Antiplatelet therapy after percutaneous coronary intervention.
EuroIntervention, 2022 Antiplatelet therapy is key to reducing local thrombotic complications and systemic ischaemic events among patients undergoing percutaneous coronary interventions (PCI), but it is inevitably associated with increased bleeding.
D. Angiolillo +4 more
semanticscholar +1 more source
Journal of The Arab Society for Medical Research, 2023 Platelets play a major role in normal hemostatic and thrombotic processes. Aggregation of platelets presents the key pathophysiological step in the development of cardiovascular diseases; hence, antiplatelet agents remain crucial in the treatment of cardiovascular diseases. They may target the three principal phases leading to
Asma Haffouz +2 more
openaire +2 more sources
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021 Background Antiplatelet therapy increases the risk of hematoma expansion in intracerebral hemorrhage (ICH) while the effect on functional outcome is uncertain.
ZheKang Law +21 more
semanticscholar +1 more source
Antiplatelet Use in Ischemic Stroke
The Annals of Pharmacotherapy, 2022 Objective: A literature review of antiplatelet agents for primary and secondary stroke prevention, including mechanism of action, cost, and reasons for lack of benefit.
Marharyta Kamarova +8 more
semanticscholar +1 more source